Eric K. Singhi and Jarushka Naidoo Highlighted Study On Pooled Analysis of Datopotamab Deruxtecan in patients with EGFR–mutated NSCLC
Eric K. Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post on X by Jarushka Naidoo, Full Professor and Consultant Medical Oncologist at Royal College of Surgeons in Irelan, adding:
“Pooled data on Dato-DXd in EGFR+ NSCLC from TROPION-Lung05 + 01
117 pts, median 3 prior lines, 82% prior osimertinib
– ORR: 43%
– DOR: 7 mo
– PFS: 5.8 moMucositis/stomatitis: 69%
Ocular events: 32%
ILD/pneumonitis: 4%”
Quoting Jarushka Naidoo‘s post.
“What is the role of Dato-Dxd in EGFR+ NSCLC?
– pooled analysis TropionLung01+05
– 117pts (med. 3 lines)
– ORR 43%, mPFS 5.8m, mOS 15.6m
– 60% stomatitis, g3+ 9%Reasonable option, though data not in the era of MARIPOSA+/-2″
Title: A pooled analysis of datopotamab deruxtecan in patients with EGFR–mutated NSCLC
Journal: Journal of Thoracic Oncology
Authors: Myung-Ju Ahn, Aaron Lisberg, Yasushi Goto, Jacob Sands, Min Hee Hong, Luis Paz-Ares, Elvire Pons-Tostivint, Maurice Pérol, Enriqueta Felip, Shunichi Sugawara, Hidetoshi Hayashi, Byoung Chul Cho, George Blumenschein Jr., Elaine Shum, Jong-Seok Lee, Rebecca S. Heist, Robin Cornelissen, Wen-Cheng Chang, Dariusz Kowalski, Hong Zebger-Gong, Michael Chargualaf, Wen Gu, Lan Lan, Paul Howarth, Richard Joseph, Isamu Okamoto
More posts featuring Eric K. Singhi and Jarushka Naidoo on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023